Tinjauan Atas Efikasi Asam Traneksamat Oral untuk Terapi Melasma
DOI:
https://doi.org/10.55175/cdk.v49i8.290Keywords:
Asam traneksamat oral, efikasi, melasmaAbstract
Melasma adalah kondisi hipermelanosit didapat berupa makula tidak merata yang umumnya simetris. Kondisi ini biasanya terlokalisasi dan bersifat kronik-residif. Di antara banyak faktor kausatif yang berperan pada patogenesis melasma, salah satu yang dianggap penting adalah paparan sinar UV pada kulit. Pengobatan melasma penuh tantangan karena sering rekuren. Asam traneksamat adalah plasmin inhibitor yang melalui sistem plasmin-aktivator plasminogen berperan mencegah induksi pigmentasi oleh radiasi UV. Artikel ini bertujuan meninjau efikasi asam traneksamat oral pada terapi melasma. Melasma is an acquired hypermelanocyte condition; generally localized, symmetrical in regular macules form, and chronic-recidive. Many causative factors may play role in the pathogenesis of melasma, one that is considered important is UV exposure. Despite several treatments available, recurrences are common. Tranexamic acid as plasmin inhibitor acts mainly via the plasminogen activator-plasmin system to prevent UV radiation-induced pigmentation. This review discuss the efficacy of oral tranexamic acid for melasma treatment.
Downloads
References
Djuanda A. Ilmu penyakit kulit dan kelamin. 6th Ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2011 .p. 289-90.
Poojary S, Minni K. Tranexamic acid in melasma: A review. JPD. 2015;2:228-32.
Passeron T. Melasma pathogenesis and influencing factors-an overview of the latest research. JEADV. 2013;27:5-6.
Dashore S, Mishira K. Tranexamic acid in melasma. Why and how? Indian J Drugs Dermatol. 2017;3:61-3.
Soundarya S, Srinivasan MS. Tranexamic acid in dermatology. Ann Trop Med & Public Health 2020;23:1-8.
Verussa MJMC, Steiner D. Oral tranexamic acid to treat melasma: A literature review. J Dermatol Surg Res Ther. 2019;2:51-8.
Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J. 2012;10:40-3.
Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial. Indian J Dermatol. 2015;60:520.
Khurana VK, Misri RR, Agarwal S, Thole AV, Kumar S, Anand T. A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma. Indian J Dermatol Venereol Leprol. 2018;85:39-43
Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36:964-70
Li Y, Sun Q, He Z, Fu L, He C, Yan Y. Treatment of melasma with oral administration of compound tanexamic aci: A preliminary clinical trial. J Eur Acad Dermatol Venereol. 2014;28:393-4.
Nagaraju D, Bhattacharjee R, Vinay K, Saikia UN, Parsad D, Kumaran MS. Efficacy of oral tranexamic acid in refractory melasma: A clinic-immuno-histopathological study. Dermatol Ther. 2018;31:e12704.
Zhu JW, Ni YJ, Tong XY, Guo X, Wu XP, Lu ZF. Tranexamic acid inhibits angiogenesis and melanogenesis in vitro by targeting VEGF receptors. Int J Med Sci. 2020;17:903-11.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.